- Context
Modafinil vs alternatives
A factual side-by-side view of five compounds people encounter in discussions of alertness. This is a comparison of mechanisms, durations and evidence quality, not a ranking, and not a recommendation.
Modafinil
Wakefulness-promoting agent
Primary Mechanism
Weak dopamine reuptake inhibition, with orexin and histamine involvement
Typical Duration
Long, commonly described as covering a working day
Evidence Base
Trials in narcolepsy, sleep apnea and shift work sleep disorder
Notable Risks
Rash, psychiatric effects, interactions through liver enzymes
Read more about modafinil
→
Armodafinil
Wakefulness-promoting agent
Primary Mechanism
The same pathways as modafinil, using the R enantiomer alone
Typical Duration
Long, with a plasma profile that differs from racemic modafinil
Evidence Base
Trials in the same sleepiness indications
Notable Risks
Broadly comparable adverse effect profile to modafinil
Read more: modafinil vs armodafinil
→
Adderall
Amphetamine salt stimulant
Primary Mechanism
Dopamine and norepinephrine release by transporter reversal, plus reuptake blockade
Typical Duration
About 4 to 6 hours for immediate release, about 12 hours for extended release
Evidence Base
Registration trials in ADHD and narcolepsy
Notable Risks
Boxed warning for abuse and addiction, cardiovascular strain, appetite and sleep disruption, withdrawal on stopping
Read more: modafinil vs Adderall
→
Caffeine
Widely available stimulant
Primary Mechanism
Adenosine receptor antagonism
Typical Duration
Short to moderate, several hours
Evidence Base
Extensive literature on alertness and vigilance
Notable Risks
Tolerance, withdrawal headache, disrupted sleep, anxiety at high doses
Read more: modafinil vs caffeine
→
L-Theanine
Amino acid, dietary supplement
Primary Mechanism
Proposed modulation of glutamate and GABA signalling
Typical Duration
Short, studied in single dose designs
Evidence Base
Small trials, often combined with caffeine, with mixed results
Notable Risks
Generally reported as well tolerated, with limited long term data
Read more: what the L-theanine evidence shows
→
Reading the comparison
Each point below explains why the rows above differ, and where the comparison breaks down.
Mechanism is not interchangeable
Modafinil and armodafinil act on monoamine and orexin systems; Adderall releases dopamine and norepinephrine directly and far more strongly; caffeine works through adenosine receptors; L-theanine is studied for effects on inhibitory signalling. These are different targets, so results from one compound do not transfer to another.
Amphetamines sit in a different risk class
Adderall is a Schedule II amphetamine with documented dependence potential, cardiovascular effects and a withdrawal pattern on discontinuation. Wakefulness-promoting agents are described in the literature as having a lower reinforcement profile, but that difference is one of degree rather than an absence of risk.
Duration changes the trade-off
Longer-acting compounds can interfere with subsequent sleep if taken late. Shorter-acting ones require repeat dosing. Duration figures in the literature are averages and vary with metabolism and formulation.
Study populations differ
Wakefulness agents have mostly been examined in sleep-deprived or clinically diagnosed groups, while caffeine and L-theanine are more often studied in rested volunteers. Baseline state shapes what any trial can detect, so results do not transfer between these settings.
Evidence quality differs sharply
Wakefulness-promoting agents have been tested in registration trials for defined indications. Supplement literature is typically smaller, shorter and more heterogeneous. Comparing them on a single scale would be misleading.